In agreement with the gain-of-function experiments, silencing FAM83A in pancreatic cancer cell lines significantly decreased the proportion of CD133+ cells, tumorsphere number and size, the proportion of SP+ cells, resistance to gemcitabine and 5-FU (Figures 3a–e) and the mRNA expression levels of pluripotency factors compared with RNAi-vector control cells (Supplementary Figure S2b). This evidence concerns the gene PROM1 and pancreatic neoplasm.